The standard of care for high-risk post-surgical BC patients includes adjuvant chemotherapy with an anthracycline-containing regimen followed or preceded by a taxane, with the addition of anti-HER2 treatment in HER2-positive disease [8,9,10]. The gene discussed is ERBB2; the disease is breast cancer.